文献速递胃肠动力与功能性疾病

低FODMAP饮食:对肠易激综合征作用机制与疗效认识的最新进展

The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS.
PubMed 文献 · Gut · 2017-06-07

综述关注饮食与肠易激综合征功能性胃肠症状的相互作用。MRI研究显示短链可发酵碳水化合物增加小肠水容量和结肠产气,在内脏高敏感者中诱发症状。低FODMAP饮食在至少10项随机对照或随机比较试验中使50%-80%的肠易激综合征患者获得临床应答,尤其改善腹胀、排气、腹泻和整体症状,但也会引起菌群和代谢组的深刻变化,其持续时间和临床意义尚不清楚。

要点

  • MRI研究显示短链可发酵碳水化合物增加小肠水容量和结肠产气,在内脏高敏感者中诱发功能性胃肠症状。
  • 至少10项随机对照试验或随机比较试验显示低FODMAP饮食使50%-80%的肠易激综合征患者获得临床应答。
  • 低FODMAP饮食可改善腹胀、排气、腹泻和整体症状,但会导致菌群和代谢组的深刻变化,其持续时间和临床意义尚不清楚。

核心结论

  • 低FODMAP饮食在至少10项随机对照试验或随机比较试验中使50%-80%的肠易激综合征患者获得临床应答,尤其改善腹胀、排气、腹泻和整体症状。
  • 近期研究显示低FODMAP饮食导致菌群和代谢组的深刻变化,其持续时间和临床意义尚不清楚。

研究设计与样本

  • 本文为综述,旨在呈现低FODMAP饮食影响肠易激综合征症状机制的最新认识、疗效的最新证据、对微生物组影响的最新发现以及未来研究领域的建议。

主要发现

  • MRI研究显示短链可发酵碳水化合物增加小肠水容量和结肠产气,在内脏高敏感者中诱发功能性胃肠症状。
  • 早期评估低FODMAP饮食疗效的研究受回顾性研究设计和缺乏对照组限制,但近期已发表设计良好的临床试验。
  • 目前至少有10项随机对照试验或随机比较试验显示低FODMAP饮食使50%-80%的肠易激综合征患者获得临床应答,尤其改善腹胀、排气、腹泻和整体症状。
  • 近期研究还显示低FODMAP饮食导致菌群和代谢组的深刻变化,其持续时间和临床意义尚不清楚。

临床怎么用

  • 短链可发酵碳水化合物的饮食限制(低FODMAP饮食)目前越来越多地用于临床实践。

局限性

  • 早期评估低FODMAP饮食疗效的研究受回顾性研究设计和缺乏对照组限制。
  • 低FODMAP饮食导致菌群和代谢组深刻变化的持续时间和临床意义尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is an intensifying interest in the interaction between diet and the functional GI symptoms experienced in IBS. Recent studies have used MRI to demonstrate that short-chain fermentable carbohydrates increase small intestinal water volume and colonic gas production that, in those with visceral hypersensitivity, induces functional GI symptoms. Dietary restriction of short-chain fermentable carbohydrates (the low fermentable oligosaccharide, disaccharide, monosaccharide and polyol (FODMAP) diet) is now increasingly used in the clinical setting. Initial research evaluating the efficacy of the low FODMAP diet was limited by retrospective study design and lack of comparator groups, but more recently well-designed clinical trials have been published. There are currently at least 10 randomised controlled trials or randomised comparative trials showing the low FODMAP diet leads to clinical response in 50%-80% of patients with IBS, in particular with improvements in bloating, flatulence, diarrhoea and global symptoms. However, in conjunction with the beneficial clinical impact, recent studies have also demonstrated that the low FODMAP diet leads to profound changes in the microbiota and metabolome, the duration and clinical relevance of which are as yet unknown. This review aims to present recent advances in the understanding of the mechanisms by which the low FODMAP diet impacts on symptoms in IBS, recent evidence for its efficacy, current findings regarding the consequences of the diet on the microbiome and recommendations for areas for future research.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017. PMID: 28592442. doi:10.1136/gutjnl-2017-313750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。